Pregnancy cases in PV: An overview
In this comprehensive blog, you will explore the various categories and scenarios involved in handling pregnancy cases within pharmacovigilance case processing. Let’s dive in!
Greetings and welcome to our ICSR community! Here, we share valuable insights on the nuances of ICSR case processing, no matter how small, to help you process cases effectively. We believe in sharing knowledge and information that we have to help our community grow.
In this comprehensive blog, you will explore the various categories and scenarios involved in handling pregnancy cases within pharmacovigilance case processing. Let’s dive in!
Here in this informative pharmacovigilance blog, where we provide a comprehensive overview of the book-in process in Individual Case Safety Report (ICSR) management. In this article, we present a step-by-step guide that simplifies the book-in process, ensuring a better understanding for all.
This blog includes: Introduction In adverse event reporting, each case often includes initial reports and multiple follow-ups. This…
This blog covers: Introduction This blog focuses on the processes involved in conducting causality assessments. You will learn…
In this article, you’ll learn how to picking receipt dates during case processing in various scenarios—a commonly confusing aspect. We will explore the complexities involved and provide clarity on this often intricate topic.
Welcome to our informative blog. Here you can learn about the difference between E2b (R2) and E2b (R3), Building upon our previous discussion about E2B, we now delve deeper into the evolution of the E2B standard.
In this blog, where you can learn the significance of receipt dates in ICSR (Individual Case Safety Report) case processing and their impact on submissions. Join us as we explore the context of case processing in related with receipt dates.
In this comprehensive blog, we explore what case linking means in the context of ICSR cases and also explain the criteria for linking cases.
Copyright © Drugvigil. All Rights Reserved.